Leuthold Group LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 11.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,303 shares of the biopharmaceutical company’s stock after acquiring an additional 1,038 shares during the period. Leuthold Group LLC’s holdings in Regeneron Pharmaceuticals were worth $7,812,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $26,000. Armstrong Advisory Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 466.7% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Trust Co. of Vermont bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. Finally, Fiduciary Financial Advisors bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Regeneron Pharmaceuticals
In related news, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $542,700. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 27,028 shares of company stock valued at $25,025,950. 6.97% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts recently commented on the company. Raymond James Financial boosted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Sanford C. Bernstein lifted their price objective on Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a “market perform” rating in a report on Monday, November 2nd. Evercore boosted their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $898.97.
Regeneron Pharmaceuticals Stock Up 1.7%
Shares of REGN opened at $919.96 on Tuesday. The company has a market capitalization of $94.72 billion, a P/E ratio of 20.31, a PEG ratio of 1.38 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $591.52 and a one year high of $991.73. The business’s 50 day simple moving average is $806.90 and its 200-day simple moving average is $743.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period last year, the firm posted $11.83 EPS. The business’s revenue was up 36.3% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.
The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Founded in 1988, Regeneron is headquartered in Tarrytown, New York.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
